Tirzepatide Side Effects: What the FDA Labels Report

There are two different incidence tables because tirzepatide is approved under two brand names, studied in two different populations. Mounjaro's table pools placebo-controlled trials in type 2 diabetes:

Zepbound's table, drawn from the obesity trials, runs roughly twice as high on nausea and adds several reactions Mounjaro's table does not list:

Hair loss is worth pausing on because it surprises people. The Zepbound label attributes it to the weight reduction rather than to tirzepatide directly, which fits the pattern of telogen effluvium after rapid weight loss from any cause.

Same molecule, same doses, very different numbers. The gap is mostly population and expectation. Diabetes trial participants were often already on metformin and other agents with their own GI profile, which lifts the placebo column and compresses the difference. Obesity trial participants were largely treatment-naive, and placebo nausea was 8% rather than 4%.

Neither table is wrong. If you want a single honest sentence: roughly one in four to one in three people report nausea on tirzepatide, most of it mild to moderate, most of it during titration.

The SURPASS analyses found GI events were typically mild to moderate, transient, and clustered in the dose-escalation period rather than spread evenly across treatment. The same pattern held across SURMOUNT-1 to -4. That is why every approved label starts at 2.5 mg for four weeks, a dose the label describes as a starting dose for treatment initiation and not intended for glycemic control or weight management on its own.

The escalation schedule is the tolerability strategy. In the phase 2 program, faster escalation with larger increments produced worse GI tolerability than the slower phase 3 scheme that made it into the label. Compressing the ladder is the single most reliable way to make tirzepatide feel worse than it needs to.

Discontinuation gives a sense of how many people could not push through. In the Zepbound obesity trials, 4.8%, 6.3% and 6.7% of patients on 5 mg, 10 mg and 15 mg permanently discontinued. On the Mounjaro side, 3.0%, 5.4% and 6.6% stopped specifically because of GI reactions, versus 0.4% on placebo.

The boxed warning is about rodents: tirzepatide causes thyroid C-cell tumors in rats, and the label states plainly that it is unknown whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans. That uncertainty is why a personal or family history of MTC, or Multiple Endocrine Neoplasia syndrome type 2, is a contraindication rather than a caution.

The Warnings and Precautions sections list, across both labels: severe gastrointestinal adverse reactions, acute kidney injury due to volume depletion, acute gallbladder disease, acute pancreatitis, hypersensitivity reactions, hypoglycemia, diabetic retinopathy complications, and pulmonary aspiration during general anesthesia or deep sedation.

The observed rates are low but not zero. Severe GI reactions occurred in 1.7% (5 mg), 2.5% (10 mg) and 3.1% (15 mg) of Zepbound patients versus 1% on placebo. Cholelithiasis was reported in 1.1% of Zepbound patients versus 1% on placebo, and cholecystitis in 0.7% versus 0.2%. Adjudicated acute pancreatitis affected 0.2% of Zepbound patients; in the Mounjaro program, 14 adjudicated events occurred in 13 patients, a rate the label expresses as 0.23 patients per 100 years of exposure.

Acute kidney injury deserves its own line because the mechanism is mundane. It has been reported after severe vomiting and diarrhea, sometimes requiring hemodialysis, in patients who became volume depleted. It is a dehydration problem before it is a kidney problem.

Hypoglycemia is not typically a tirzepatide-alone event. The risk appears when it is combined with insulin or an insulin secretagogue such as a sulfonylurea, and the label anticipates a dose reduction of the companion drug rather than of tirzepatide.

Oral contraceptives. Tirzepatide delays gastric emptying, and the labels state this may reduce the efficacy of oral hormonal contraceptives. The recommendation is to switch to a non-oral method, or add a barrier method, for 4 weeks after starting and for 4 weeks after each dose escalation. Non-oral hormonal contraception is not expected to be affected. This is a real interaction that people on GLP-1 forums routinely have never heard of.

Anesthesia. Retained gastric contents have been reported despite standard preoperative fasting, which is why pulmonary aspiration during general anesthesia or deep sedation is now a labeled warning. Anyone scheduling surgery, an endoscopy, or a dental procedure under sedation should tell the team they are on tirzepatide.

The labels also state that tirzepatide has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and is not recommended in that group.

Here is the part specific to this site. The FDA has documented dosing errors with compounded and unapproved GLP-1 products, and its stated causes are not exotic: patients measuring and self-administering incorrect doses, clinicians miscalculating, conversion from milligrams to other units of measurement, products supplied in varying concentrations, and multiple-dose vials. FDA has described the resulting adverse events as including severe nausea, severe vomiting and severe hypoglycemia, some requiring hospitalization.

The specific trap is the word "units." An insulin syringe is graduated in insulin units, which are a property of the syringe barrel, not a property of tirzepatide. A chart that says "draw 20 units for 5 mg" is only true at one specific concentration. Reconstitute the same 10 mg vial with 1 mL instead of 2 mL and that same 20 units delivers double the dose. This is exactly how a person aiming for a 2.5 mg starting dose ends up with a 5 mg or 7.5 mg exposure and a week of vomiting they attribute to the drug being intolerable.

If you are reconstituting anything, the concentration has to be recomputed for your vial and your diluent volume, every time. Our tirzepatide calculator does that arithmetic, the reconstitution guide covers the method, and the syringe measurement guide explains why the same mark on two syringes is not the same dose. The tirzepatide dosage reference collects the escalation schedule as the labels describe it.

None of this is dosing advice. Which dose, how fast to escalate, whether to escalate at all, and what to do when side effects appear are prescriber decisions made with your history in front of them.

Long-term safety data on tirzepatide obtained outside the approved supply chain essentially does not exist. Everything above comes from trials of a manufactured, sterile, concentration-verified product. Research-grade vials carry no titration schedule, no verified concentration, and in some cases no verified identity, and FDA has raised concerns about unapproved salt forms. Nobody has published incidence tables for that population, so anyone quoting side effect rates for a research vial is quoting Lilly's trial data and hoping it transfers.